Menu

Cancer Tissue Repository Launched

The Dana-Farber Cancer Institute will store tissue samples from patients with leukemia and lymphoma from which scientists can make patient-derived mouse models.

Apr 11, 2016
Jef Akst

WIKIMEDIA, RAMAOne method that is growing in popularity for testing drugs on specific cancer types is the creation of patient-derived xenografts (PDXs), in which researchers implant bits of cancerous tissue extracted from patients into mice for study. Today (April 11), the Dana-Farber Cancer Institute announced the launch of an open-source public repository of biopsy tissue collected from patients with leukemia and lymphoma. Researchers can register for the database, called the Public Repository of Xenografts (PRoXe), use its Web portal to search for PDX models of specific subtypes of blood cancers, and order frozen cells from which they can create xenograft mouse models.

“About 90 percent of compounds that show anti-cancer activity in pre-clinical tests don’t work when given to patients,” said Dana-Farber’s David Weinstock said in a press release. “By trying drugs in PDX models, we can ‘mimic’ large and expensive human clinical trials and get answers about efficacy more quickly, less expensively and without the need for patients to get investigational drugs that won’t work.” Weinstock and his colleagues published details of the new repository today (April 11) in Cancer Cell; a total of 95 different researchers from 14 institutions are listed as coauthors.

For now, PRoXe includes only blood cancers, which are easier to biopsy and successfully transplant than solid tumors. But Weinstock noted in the press release that he and his colleagues are now in talks with several universities to expand the repository to include other biopsy tissues.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.